Cabaletta Bio, Inc. (CABA)
| Market Cap | 146.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -126.76M |
| Shares Out | 89.94M |
| EPS (ttm) | -2.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 930,391 |
| Open | 1.610 |
| Previous Close | 1.600 |
| Day's Range | 1.560 - 1.630 |
| 52-Week Range | 0.986 - 8.770 |
| Beta | 2.70 |
| Analysts | Strong Buy |
| Price Target | 14.43 (+785.28%) |
| Earnings Date | Aug 7, 2025 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclero... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price target is $14.43, which is an increase of 785.28% from the latest price.
News
Cabaletta Bio Announces Pricing of Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first ...
Cabaletta Bio: Sector Headwinds And Funding Issues
Cabaletta Bio's CAR T-cell therapy shows durable efficacy in autoimmune diseases, with manageable side effects and promising early clinical data updates. The company plans a BLA submission for myositi...
Cabaletta Bio Announces Proposed Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first ...
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the ...
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
– Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune di...
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption Program (TAP) on its automated cel...
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining ...
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining ...
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
Cabaletta Bio: Finding Optimism In Dire Straits
Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough ca...
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, t...
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapi...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling –
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug...
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials –
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ tria...
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...